立方制药：收到原料药上市申请批准通知书

Core Viewpoint - Recently, the company received the approval notice for the listing application of Procaine Hydrochloride from the National Medical Products Administration, which will enhance its product pipeline and competitiveness in formulations [1] Group 1 - The approved raw material is a potent ester-type local anesthetic primarily used for surface anesthesia in ophthalmology [1] - The approval will further enrich the company's raw material product line [1] - The new product is expected to strengthen the competitiveness of the company's formulation varieties [1]